Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board
- 1 February 2019
- journal article
- editorial
- Published by Elsevier in Trends in Immunology
- Vol. 40 (2) , 83-85
Abstract
No abstract availableKeywords
Funding Information
- AIRC
- Italian Ministry of Health
- MIUR
This publication has 10 references indexed in Scilit:
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsCell, 2018
- Fundamental Mechanisms of Immune Checkpoint Blockade TherapyCancer Discovery, 2018
- PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole SectionsJournal of Thoracic Oncology, 2018
- NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute LeukemiaTrends in Immunology, 2018
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Natural killer cells and dendritic cells: rendezvous in abused tissuesNature Reviews Immunology, 2002
- Transforming growth factor-β-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytesEuropean Journal of Immunology, 1999
- HLA class I-specific inhibitory receptors in human T lymphocytes: Interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cellsProceedings of the National Academy of Sciences, 1998
- Interleukin‐15‐induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2‐A as the only HLA class I‐specific inhibitory receptorEuropean Journal of Immunology, 1997
- Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine productionInternational Immunology, 1995